arrow
C

Cristina Suárez

harvard university medical affiliates
H指数:54
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

34 Belzutifan Plus Lenvatinib Versus Cabozantinib in Post–PD-(L)1 Renal Cell Carcinoma: Health-Related Quality-of-Life Outcomes in the Phase 3 LITESPARK-011 Study

34 Belzutifan联合仑伐替尼与卡博替尼在PD-(L)1后肾细胞癌中的比较:LITESPARK-011 III期研究中健康相关生活质量结局

2026-09-020
OAAI
66 Relationship Between Health-related Quality of Life and Efficacy in the Phase 3 LITESPARK-005 Study of Belzutifan versus Everolimus in Previously Treated Advanced Clear Cell Renal Cell Carcinoma

66 健康相关生活质量与疗效在LITESPARK-005研究(比较Belzutifan与Everolimus在先前治疗过的晚期透明细胞肾细胞癌中的效果)第三阶段的关系

2026-09-020
OAAI
88 PEAK-1 (NCT07011719): A Randomized, Double-Blind, Active-Control Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma

PEAK-1 (NCT07011719):一项关于卡沙替法尼和卡博赞替尼与安慰剂和卡博赞替尼在晚期透明细胞肾细胞癌患者中进行的随机、双盲、活性对照III期试验

2026-09-020
OAAI
85 Phase 3 LITESPARK-033 (NCT07227402) Study of Belzutifan Plus Zanzalintinib Versus Cabozantinib for Recurrent Clear Cell Renal Cell Carcinoma During or After Adjuvant Anti–PD-(L)1 Therapy

85 LITESPARK-033(NCT07227402)III期研究:比较贝舒替班联合赞赞林替尼与卡博赞替尼治疗接受辅助抗PD-(L)1治疗后复发透明细胞肾细胞癌的疗效

2026-09-020
OAAI
1 Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Renal Cell Carcinoma: Patient-Reported Outcomes in LITESPARK-022

1 帕博利珠单抗联合贝舒妥昔单抗与帕博利珠单抗联合安慰剂作为肾细胞癌辅助治疗:LITESPARK-022研究中的患者报告结局

2026-09-020
OAAI
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

高级泌尿肿瘤共识会议(AUC3)2025:肾细胞癌和尿路肿瘤管理的专家共识

2025-12-130
OAAI
Novel pembrolizumab-based treatments as first-line therapy in advanced clear cell renal cell carcinoma: Substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial

新型基于pembrolizumab的治疗方案作为晚期透明细胞肾细胞癌的一线疗法:开放标签、伞形平台、I/II期KEYMAKER-U03试验的子研究03A

2025-10-180
PRE
Subgroup analysis of the efficacy and safety of cabozantinib ± atezolizumab in patients from CONTACT-03 who received first-line treatment with immuno-oncology-based combinations

卡博替尼±阿替利珠单抗在CONTACT-03研究中接受以免疫肿瘤为基础的联合方案一线治疗患者的疗效和安全性亚组分析

2025-10-010
OAAI
Pembrolizumab plus lenvatinib for previously untreated advanced non-clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study

帕博利珠单抗联合仑伐替尼用于初治的透明细胞肾细胞癌以外的晚期肾细胞癌:KEYNOTE-B61研究的3年随访结果

2025-10-012
OAAI
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

来自随机III期CheckMate 9ER试验的尼鲁单抗联合卡博赞替尼治疗晚期肾细胞癌的最终分析

2025-09-230
OAAI
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study

卡博替尼治疗晚期肾细胞癌在西班牙和葡萄牙真实世界实践中的有效性与安全性:SOGUG-SPRWEC研究

2025-09-010
PRE
First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial

一线帕博利珠单抗联合伦伐替尼治疗晚期非透明细胞肾细胞癌:KEYNOTE-B61 II期试验的更新结果

2025-07-240
PRE
Corrigendum to “Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients” [Eur. Urol. Oncol. 7 (2024) 954–964]

勘误:关于“基于RB1、PTEN和TP53在转移性激素敏感性前列腺癌患者中开发并独立验证预后基因表达签名”[Eur. Urol. Oncol. 7 (2024) 954–964]

2025-05-010
PRE
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

非透明细胞肾细胞癌中,伊匹木单抗/纳武利尤单抗对比标准护理的 prospective randomized phase-II trial - SUNNIFORECAST trial 的结果

2025-04-010
OA
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma

晚期肾细胞癌患者接受乐伐替尼治疗后后续治疗的疗效

2024-12-070
PRE
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
2024-08-225
PRE
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients
2024-08-014
OA